Actively Recruiting
Evaluation of ADX-038 Alone and Combined with Telitacicept for Chinese Adults With Complement-Mediated Kidney Diseases
Led by ADARx Pharmaceuticals, Inc. · Updated on 2026-09-03
30
Participants Needed
9
Research Sites
27 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, effectiveness, pharmacokinetics, and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. This Phase 2 study includes Chinese adults diagnosed with IgA nephropathy, complement 3 glomerulopathy C3G, and immune complex membranoproliferative glomerulonephritis IC-MPGN. The study aims to better understand how ADX-038 works alone and in combination with telitacicept to treat these kidney conditions. The study has two parts Part A tests ADX-038 alone, while Part B tests ADX-038 combined with telitacicept. Both treatments are given to participants who meet the criteria. The study is non-randomized and parallel in design, allowing comparison of the two treatment approaches. Part A lasts 24 months, and Part B lasts 15 months, during which participants receive the study drugs. Participants will be monitored throughout the study for safety and tolerability of the treatments. Researchers will collect data on kidney function and other health measures to evaluate treatment impact. The study includes assessments such as kidney biopsies and vaccinations as required. Total participation may last up to two years depending on the treatment part assigned.
CONDITIONS
Brief Title
Chinese Adults With Kidney Disease
Research Team
S
Stephanie Leyva
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here